Felix Feng

May 22, 2024 | europeanurology.com | Adam B. Weiner |Andrew Armstrong |Alberto Bossi |La Garenne Colombes |Philip Cornford |Felix Feng | +9 more

Abstract Biochemical recurrence (BCR) after primary definitive treatment for prostate cancer (PCa) is a heterogeneous disease state. While BCR is associated with worse oncologic outcomes, risk factors that impact outcomes can vary significantly, necessitating avenues for risk stratification. We sought to identify prognostic risk factors at the time of recurrence after primary radical prostatectomy or radiotherapy, and prior to salvage treatment(s), associated with adverse oncologic outcomes.

May 17, 2024 | europeanurology.com | Sabine D. Brookman-May |Janssen Research |Stephen J. Freedland |Spring House |Marc E. Buyse |Branko Miladinovic | +5 more

To read this article in full you will need to make a paymentSubscribe to European UrologyReferencesMetastasis-free survival is a strong surrogate of overall survival in localized prostate cancer. J Clin Oncol. 35: 3097-3104ICECaP-2: Validation of metastasis-free survival (MFS) as a surrogate for overall survival (OS) in localized prostate cancer (LPC) in a more contemporary era. Ann Oncol.

Feb 22, 2024 | nature.com | Meng Zhang |David Quigley |Felix Feng

AbstractMetastatic castration-resistant prostate cancer (mCRPC) is a lethal form of prostate cancer. Although long-noncoding RNAs (lncRNAs) have been implicated in mCRPC, past studies have relied on bulk sequencing methods with low depth and lack of single-cell resolution. Hence, we performed a lncRNA-focused analysis of single-cell RNA-sequencing data (n = 14) from mCRPC biopsies followed by integration with bulk multi-omic datasets.

Feb 8, 2023 | urotoday.com | Felix Feng

Felix Feng joins Alicia Morgans to discuss how the application of artificial intelligence (AI) is transformative in prostate cancer care. Dr. Feng focuses on how AI will assist physicians in their goal to personalize treatment for every individual patient. Dr. Feng explains how AI is currently used as a prognostic tool in the identification of recurrence rates for patients, or identifying the rate of metastasis for a patient in 5-10 years.